Results 201 to 210 of about 118,448 (336)

GABA in the Deep Layers of the Superior Colliculus/Mesencephalic Reticular Formation Mediates the Enhancement of Startle by the Dopamine D₁Receptor Agonist SKF 82958 in Rats [PDF]

, 2000
Edward G. Meloni, Michael J. Davis
openalex   +1 more source

Microstructural Changes in the Tuberal Hypothalamus Correlate with Daytime Sleepiness in Lewy Body Disorders

Movement Disorders, EarlyView.
Abstract Background Excessive daytime sleepiness (EDS) is a disabling symptom of Lewy body disorders (LBD). The hypothalamus is a key sleep–wake regulator and is involved in Lewy pathology, but its contribution to EDS in LBD remains unclear. Objectives To use diffusion‐weighted magnetic resonance imaging (MRI) to detect hypothalamic microstructure and ...
Jesse S. Cohen, Hamsanandini Radhakrishnan, Christopher A. Olm, Sandhitsu R. Das, Philip A. Cook, David A. Wolk, Daniel Weintraub, David J. Irwin, Corey T. McMillan   +8 more
wiley   +1 more source

Impulse control and correlation to dopamine agonist serum concentrations in people with Parkinson's disease. [PDF]

J Neurol
Staubo SC, Fuskevåg OM, Toft M, Lie IH, Alvik KMJ, Jostad P, Tingvoll SH, Lilleng H, Rosqvist K, Størset E, Odin P, Dietrichs E, Dietrichs ES.   +12 more
europepmc   +1 more source

The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas. [PDF]

BMC Endocr Disord, 2021
Wang S, Wang A, Zhang Y, Zhu K, Wang X, Chen Y, Wu J.   +6 more
europepmc   +1 more source

Disease‐Modifying Trials in Treated Parkinson's Disease: “Stable Treated” Does Not Equate with Biological Stability

Movement Disorders, EarlyView.
Abstract Traditionally, clinical trials of putative disease‐modifying therapies in Parkinson's disease have enrolled untreated patients at the earliest clinical stages of their disease. Due to a number of challenges inherent with this approach, there has been a recent move to a different study design, enrolling patients who are already taking “stable ...
M. Maral Mouradian, A. Jon Stoessl, Anthony E. Lang   +2 more
wiley   +1 more source

Sex-based disparities in dopamine agonist response in patients with restless legs syndrome. [PDF]

J Sleep Res
Mogavero MP, Antelmi E, Lanza G, Marelli S, Castelnuovo A, Tinazzi M, DelRosso LM, Silvestri R, Ferri R, Ferini Strambi L.   +9 more
europepmc   +1 more source

Prolactin-Secreting Leiomyoma Causing Hyperprolactinaemia Unresponsive to Dopamine Agonist Therapy and Resolution following Myomectomy. [PDF]

Case Rep Endocrinol, 2021
Barry L, Pather S, Gargya A, Marren A.
europepmc   +1 more source

Transcriptional Regulation of the Human PRL-Releasing Peptide (PrRP) Receptor Gene by a Dopamine 2 Receptor Agonist: Cloning and Characterization of the Human PrRP Receptor Gene and Its Promoter Region [PDF]

, 2002
Atsushi Ozawa, Masanobu Yamada, Teturou Satoh, Tsuyoshi Monden, Koshi Hashimoto, Hideaki Kohga, Yasuhiro Hashiba, Tomio Sasaki, Masatomo Mori   +8 more
openalex   +2 more sources

The Activation of p300 Enhances the Sensitivity of Pituitary Adenomas to Dopamine Agonist Treatment by Regulating the Transcription of DRD2. [PDF]

Int J Mol Sci
Li S, Li X, Wang Q, Jiang Q, Wang Z, Xu L, Huang Y, Lei T.   +7 more
europepmc   +1 more source

Long‐duration effect and the postsynaptic compartment: Study using a dopamine agonist with a short half‐life [PDF]

, 2001
Fabrizio Stocchi, Laura Vacca, Alfredo Berardelli, Francesca De Pandis, Stefano Ruggieri   +4 more
openalex   +1 more source